Loading, Please Wait...
DALLAS, July 23, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Puration, Inc. (USOTC: PURA) (”PURA”) today confirmed the company has added CBD infused coffee and CBD infused beer to the list of new beverage developments. Last week, PURA announced plans to introduce a CBD infused beer in partnership with an existing beer producer. In similar fashion, PURA is partnering with an existing coffee producer to introduce a CBD infused coffee. PURA is a leading CBD infused beverage company having produced over $1 million in CBD Beverages in the United States last year. PURA has targeted $4 million in sales for 2019. The company plans to release a management presentation next week with more details on the coffee and beer initiatives.
PURA Speculative Buy Recommendation and $0.25 PPS Target w/Potential to $0.35
Goldman Small Cap Research recently released a new research report recommending PURA as a Speculative BUY with a $0.25 PPS Target. Goldman Small Cap Research further reports that the shares of PURA “have the potential to reach the $0.35 mark.” The report highlights PURA’s growing EVERx CBD Sports Water sales and the coming introduction of new beverages as well as the potential for the company to exceed its 2019 sales targets through the pending doubling of its production capacity and through planned acquisitions.
For more information on Puration, visit http://www.purationinc.com
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.